Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AF

Background: Patient-reported outcomes and satisfaction are important in both trials and clinical practice and may be associated with treatment adherence. Methods: ROCKET-AF was a randomized, double-blind trial of rivaroxaban versus warfarin for prevention of thromboembolism in patients with atrial fibrillation. In a substudy, we compared treatment satisfaction scores: Anti-Clot Treatment Scale (ACTS) and Treatment Satisfaction Questionnaire for Medication version II (TSQM II). Patient-driven discontinuation included stopping study drugs due to withdrawal of consent, non-compliance, or loss to follow-up. Rates of discontinuation were calculated for participants above and below the median scores for each scale. Results: Of 14,264 patients in ROCKET AF, 1,181 (8.3%; median age 75 years; 34% women) patients completed both the ACTS and TSQM II questionnaires 4 weeks after starting the study drug. Over a median follow-up of 1.6 years, 450 premature study drug discontinuations occurred, 116 (26%) patient-driven. Patients less satisfied with treatment by the ACTS Benefits and Burdens and TSQM II scales had higher rates of study drug discontinuation ( Table ). Conclusions: Patient-reported satisfaction was lower in patients with study drug discontinuation, suggesting that collecting patient-reported outcomes early in clinical trials may guide interventions that improve adherence and clinical outcomes.

Download Full-text

Quality of life, effectiveness and patient reported outcomes of antiemetic prophylaxis with NEPA within the German NIS AkyPRO: post-hoc analysis of patients receiving carboplatin-based chemotherapy

10.1055/s-0040-1710726 ◽

2020 ◽

Author(s):

J Schilling ◽

R Lorenz ◽

D Rezek ◽

L Bauer ◽

D Hornung ◽

...

Keyword(s):

Quality Of Life ◽

Patient Reported Outcomes ◽

Life Effectiveness ◽

Post Hoc Analysis ◽

Antiemetic Prophylaxis ◽

Patient Reported ◽

Post Hoc

Download Full-text

Exploring the Relationship between Disease Awareness and Outcomes in Patients with Chronic Obstructive Pulmonary Disease

Respiration ◽

10.1159/000513953 ◽

2021 ◽

Vol 100 (4) ◽

pp. 291-297

Author(s):

Ilaria Baiardini ◽

Marco Contoli ◽

Angelo Guido Corsico ◽

Carla Scognamillo ◽

Fabio Ferri ◽

...

Keyword(s):

Chronic Obstructive Pulmonary Disease ◽

Pulmonary Disease ◽

Treatment Satisfaction ◽

Illness Perception ◽

Chronic Obstructive ◽

Obstructive Pulmonary Disease ◽

Post Hoc Analysis ◽

Disease Awareness ◽

Patient Reported ◽

Post Hoc

Background: Disease awareness is a challenge in the management of chronic obstructive pulmonary disease (COPD). Objectives: The aim of this analysis was to explore the association between COPD optimal and suboptimal awareness, clinical parameters, and the following patient-reported outcomes: modified Medical Research Council (mMRC), Treatment Satisfaction Questionnaire (TSQM-9), COPD Assessment Test (CAT), Morisky Medication-Taking Adherence Scale (MMAS-4), and Brief Illness Perception Questionnaire (B-IPQ). Methods: This post hoc analysis of the SAT study included all enrolled patients for whom awareness (Disease Awareness in COPD Questionnaire – DACQ) was assessed at baseline and 12 months. DACQ scores ≥80 were considered an indicator of an optimal awareness. Results: 367 patients (25.8% women, median age 72 years) were included in the analysis. At enrollment, 74 patients (20.2%) had a DACQ score ≥80. Patients with suboptimal awareness, compared to those in which awareness was optimal, had higher median scores for CAT (p = 0.0001) and mMRC (p = 0.0031), a lower median TSQM-9 global score (p < 0.0001), and higher median B-IPQ score (p < 0.0001). The proportion of patients who had exacerbations during the previous year was higher in patients with suboptimal COPD awareness than in those with DACQ score ≥80 (42.8 vs. 21.4%, p = 0.0009). During the 12-month observation period, illness perception, adherence, and treatment satisfaction were found to be independent factors significantly associated with level of disease awareness. Conclusion: The results of our post hoc analysis suggest that patients’ awareness of their COPD disease is related to both clinical outcomes and how they perceive and manage their condition.

Download Full-text

PND38 LONGITUDINAL PATIENT-REPORTED OUTCOMES (PRO) IN SUBJECTS WITH REFRACTORY PAIN ASSOCIATED TO TRIGEMINAL NEURALGIA: A POST-HOC ANALYSIS OF A 12-WEEK PROSPECTIVE STUDY IN PRIMARY CARE SETTING (PCS) UNDER ROUTINE MEDICAL PRACTICE

Value in Health ◽

10.1016/s1098-3015(10)65376-4 ◽

2007 ◽

Vol 10 (6) ◽

pp. A392

Author(s):

MT Saldaña ◽

C Pérez ◽

A Navarro ◽

S Martínez ◽

J Rejas

Keyword(s):

Primary Care ◽

Trigeminal Neuralgia ◽

Patient Reported Outcomes ◽

Care Setting ◽

Primary Care Setting ◽

Post Hoc Analysis ◽

Refractory Pain ◽

Patient Reported ◽

Routine Medical Practice ◽

Post Hoc

Download Full-text

Achieving Hidradenitis Suppurativa Response Score is Associated with Significant Improvement in Clinical and Patient-reported Outcomes: Post Hoc Analysis of Pooled Data From PIONEER I and II

Acta Dermato Venereologica ◽

10.2340/00015555-3012 ◽

2018 ◽

Vol 98 (10) ◽

pp. 932-937 ◽

Cited By ~ 6

Author(s):

A Kimball ◽

T Tzellos ◽

B Calimlim ◽

H Teixeira ◽

Z Geng ◽

...

Keyword(s):

Patient Reported Outcomes ◽

Hidradenitis Suppurativa ◽

Post Hoc Analysis ◽

Pooled Data ◽

Patient Reported ◽

Post Hoc ◽

Response Score

Download Full-text

1374. Integrated Safety Summary of Omadacycline: A Novel Aminomethylcycline Antibiotic

Open Forum Infectious Diseases ◽

10.1093/ofid/ofy210.1205 ◽

2018 ◽

Vol 5 (suppl_1) ◽

pp. S421-S421 ◽

Cited By ~ 1

Author(s):

Steven Opal ◽

Thomas M File ◽

Tom Van Der Poll ◽

Paul McGovern ◽

Evan Tzanis ◽

...

Keyword(s):

Adverse Events ◽

Fungal Infections ◽

Vital Signs ◽

Study Drug ◽

Drug Discontinuation ◽

Once Daily ◽

Atypical Pathogens ◽

Safety Parameters ◽

Study Drug Discontinuation ◽

Electrocardiogram Ecg

Abstract Background Omadacycline (OMC) is a novel aminomethylcycline with activity against Gram-positive, many Gram-negative, anaerobic, and atypical pathogens. It is in clinical development as once-daily oral (PO) and intravenous (IV) monotherapy for acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). Cumulative safety results from Phase 3 clinical trials are reported. Methods This pooled safety analysis is based on 2,150 subjects: OASIS-1 (N = 645), OASIS-2 (N = 735) in ABSSSI; OPTIC (N = 770) in CABP. Comparators were linezolid (LZD) 600 mg IV then PO in ABSSSI (n = 689); moxifloxacin (MOX) 400 mg IV then PO in CABP (n = 388). Safety parameters included treatment-emergent adverse events (TEAEs), laboratory evaluations, vital signs, and electrocardiogram (ECG) findings. Results A total of 1,073 subjects received OMC: 705 received OMC IV then PO (ABSSSI, n = 323; CABP, n = 382); 368 received OMC PO only for ABSSSI. Overall, 60.6% were male and 91.6% white; mean age ranges were 44.7–45.1 and 60.9–62.1 years in ABSSSI and CABP studies, respectively. TEAEs were observed in 47.5% (OMC), 41.2% (LZD), and 48.5% (MOX) of subjects, with gastrointestinal events the most common TEAEs. Serious TEAEs were low (3.6% OMC, 1.9% LZD, 6.7% MOX). Nausea (14.9% OMC, 8.7% LZD, 5.4% MOX) and vomiting (8.3% OMC, 3.9% LZD, 1.5% MOX) were the most frequently reported TEAEs. Diarrhea was observed in 2.4% OMC, 2.9% LZD, and 8.0% MOX subjects, with no cases of Clostridium difficile in OMC-treated subjects. Most TEAEs were mild to moderate and did not result in study drug discontinuation (3.1% OMC, 1.5% LZD, 7.0% MOX); 4 OMC, 1 LZD, and 0 MOX subjects discontinued for nausea and vomiting. Frequency of hepatic TEAEs was similar for OMC, LZD, and MOX: 4.3% OMC, 4.1% LZD, and 4.5% MOX subjects had post-baseline ALT >3× upper limit of normal. Vital signs and ECGs had comparable clinically notable values post-baseline in each treatment group. Known tetracycline class adverse events such as fungal infections were similar in all groups. Conclusion Pooled analyses demonstrate a favorable OMC safety profile, consistent with its tetracycline heritage. OMC was generally well tolerated in subjects with ABSSSI and CABP, with infrequent treatment discontinuations. Disclosures T. M. File Jr., BioMerieux: Consultant, Consulting fee; Curetis: Consultant, Consulting fee; Melinta Therapeutics: Consultant, Consulting fee; Merck: Consultant, Consulting fee; Motif Bio: Consultant, Consulting fee; Nabriva Therapeutics: Consultant and Investigator, Consulting fee and Research grant; Paratek Pharmaceuticals: Consultant, Consulting fee; Pfizer: Consultant, Consulting fee. T. Van Der Poll, Paratek Pharmaceuticals: Consultant, Consulting fee. P. McGovern, Paratek Pharmaceuticals: Employee, Salary. E. Tzanis, Paratek Pharmaceuticals: Employee, Salary.

Download Full-text

684. Cardiac Safety in Adults with Community-Acquired Bacterial Pneumonia (CABP) Treated with Lefamulin (LEF) or Moxifloxacin (MOX): Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Results

Open Forum Infectious Diseases ◽

10.1093/ofid/ofz360.752 ◽

2019 ◽

Vol 6 (Supplement_2) ◽

pp. S311-S311

Author(s):

Borje Darpo ◽

Anita F Das ◽

Daniel Stein ◽

Jennifer Schranz ◽

Steven P Gelone

Keyword(s):

Torsade De Pointes ◽

Significant Risk ◽

Study Drug ◽

Qt Prolongation ◽

Drug Discontinuation ◽

Cardiac Safety ◽

Study Results ◽

Minute Interval ◽

Clinically Significant ◽

Study Drug Discontinuation

Abstract Background Preclinical data suggest potential effects of LEF on cardiac interval parameters. We therefore assessed LEF cardiac safety from the LEAP 1/2 trials. Methods In LEAP 1, PORT III–V patients received LEF 150mg IV q12h for 5–7 days or MOX 400mg IV q24h for 7 days, with optional IV-to-oral switch (600mg LEF q12h or 400 mg MOX q24h). In LEAP 2, PORT II–IV patients received oral LEF 600mg q12h for 5 days or oral MOX 400mg q24h for 7 days. Patients with known QT prolongation or on medication with potential to prolong the QT interval were excluded as per MOX label. After 5 minutes of rest in the supine position, triplicate 12-lead ECGs were obtained within a 5-minute interval at Screening in both studies, on Days 1/3 in LEAP 1 (predose and ≤15 minutes after first IV dose), and on Days 1/4 in LEAP 2 (predose and 1–3 hours after first oral dose), and sent to a central ECG reader for adjudication. Results Of 1,282 randomized/treated patients (n = 641/group), 1,274 had baseline (BL) and post-BL ECG data (n = 636 LEF, n = 638 MOX). Consistent with the resolution of infection, ECGs revealed mean reductions of 7–8 beats/minute for both groups in both studies. The largest mean change in QTcF from BL to post-BL was on Day 3 in LEAP 1 (13.6 and 16.4 msec with IV LEF and MOX, respectively) and on Day 4 in LEAP 2 (9.3 and 11.6 msec with oral LEF and MOX, respectively). The proportion of patients meeting potentially important post-BL QTcF values/changes was comparable between treatment groups (table). In the standardized MedDRA query of Torsade de pointes/QT prolongation (broad), the most common treatment-emergent adverse event was ECG QT prolonged (n = 4 LEF, n = 5 MOX). All events were nonserious and mild or moderate in severity. 6 events were considered study drug related (n = 4 LEF, n = 2 MOX). 5 events led to study drug discontinuation (n = 2 LEF, n = 3 MOX). In 2 patients with cardiovascular disease, 1 had ventricular arrhythmia on Day 20 (18 days after last LEF dose) and 1 had cardiac arrest on Day 18 (9 days after last MOX dose); both events were fatal and considered unrelated to study drug by investigator. Conclusion Mild prolongation of the QTcF interval was seen with LEF and MOX, with somewhat smaller effects seen with LEF. Given the small effect, LEF is unlikely to pose a clinically significant risk of ventricular proarrhythmia with appropriate precautions and use. Disclosures All authors: No reported disclosures.

Download Full-text